[go: up one dir, main page]

PE20210337A1 - CASETES DE EXPRESION DE alfa-GLUCOSIDASA DE ACIDO OPTIMIZADO CON CODON Y METODOS DE USO DEL MISMO - Google Patents

CASETES DE EXPRESION DE alfa-GLUCOSIDASA DE ACIDO OPTIMIZADO CON CODON Y METODOS DE USO DEL MISMO

Info

Publication number
PE20210337A1
PE20210337A1 PE2020001867A PE2020001867A PE20210337A1 PE 20210337 A1 PE20210337 A1 PE 20210337A1 PE 2020001867 A PE2020001867 A PE 2020001867A PE 2020001867 A PE2020001867 A PE 2020001867A PE 20210337 A1 PE20210337 A1 PE 20210337A1
Authority
PE
Peru
Prior art keywords
methods
glucosidase
nucleic acids
codon
same
Prior art date
Application number
PE2020001867A
Other languages
English (en)
Inventor
Xavier Anguela
Sean Armour
Jayme Nordin
Original Assignee
Spark Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spark Therapeutics Inc filed Critical Spark Therapeutics Inc
Publication of PE20210337A1 publication Critical patent/PE20210337A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion proporciona acidos nucleicos que codifican la alfa-glucosidasa acida (GAA). En ciertas modalidades, los acidos nucleicos tienen mas de aproximadamente 86% de identidad de secuencia con una secuencia seleccionada del grupo que consiste en cualquiera de las secuencias expuestas como SEC ID NOs: 1-5. En ciertas modalidades, los acidos nucleicos que codifican la alfa-glucosidasa (GAA) contienen menos de 127 dinucleotidos CpG. Tambien se proporcionan casetes de expresion, vectores, celulas y lineas celulares y metodos para usar dichos acidos nucleicos que codifican la alfa-glucosidasa acida (GAA)
PE2020001867A 2018-05-16 2019-05-15 CASETES DE EXPRESION DE alfa-GLUCOSIDASA DE ACIDO OPTIMIZADO CON CODON Y METODOS DE USO DEL MISMO PE20210337A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862672419P 2018-05-16 2018-05-16
US201862734454P 2018-09-21 2018-09-21
PCT/US2019/032502 WO2019222411A1 (en) 2018-05-16 2019-05-15 Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same

Publications (1)

Publication Number Publication Date
PE20210337A1 true PE20210337A1 (es) 2021-02-19

Family

ID=68540790

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001867A PE20210337A1 (es) 2018-05-16 2019-05-15 CASETES DE EXPRESION DE alfa-GLUCOSIDASA DE ACIDO OPTIMIZADO CON CODON Y METODOS DE USO DEL MISMO

Country Status (17)

Country Link
US (2) US12084693B2 (es)
EP (1) EP3794043A4 (es)
JP (2) JP2021523718A (es)
KR (1) KR20210021310A (es)
CN (1) CN112334489A (es)
AU (1) AU2019268363A1 (es)
BR (1) BR112020023393A2 (es)
CA (1) CA3100213A1 (es)
CL (1) CL2020002973A1 (es)
CO (1) CO2020015707A2 (es)
MX (1) MX2020012332A (es)
MY (1) MY207355A (es)
PE (1) PE20210337A1 (es)
PH (1) PH12020551957A1 (es)
SG (1) SG11202011191WA (es)
TW (1) TW202016310A (es)
WO (1) WO2019222411A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3066569A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
KR20250140631A (ko) 2018-05-17 2025-09-25 리제너론 파마슈티칼스 인코포레이티드 항-cd63 항체, 콘쥬게이트, 및 이의 용도
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
BR112021003399A2 (pt) 2018-08-24 2021-05-18 Spark Therapeutics, Inc. sequências de promotores otimizadas, construtos de expressão livres de íntron e métodos de uso
EP3996696A1 (en) * 2019-07-09 2022-05-18 Genethon Treatment of glycogen storage disease (gsd)
BR112022011760A2 (pt) * 2019-12-20 2022-08-30 Codexis Inc Fragmento de alfa glicosidase ácida recombinante e/ou de alfa glicosidase ácida recombinante biologicamente ativa, alfa glicosidase ácida recombinante, composição, sequência polinucleotídica recombinante, vetor de expressão, vetor de expressão pdh, célula hospedeira, método para produzir uma variante de alfa glicosidase ácida recombinante, variante de alfa glicosidase ácida recombinante, composição farmacêutica para o tratamento da doença de pompe, composição farmacêutica, método para tratar e/ou prevenir os sintomas da doença de pompe em um indivíduo, e, uso das composições
JP2024504611A (ja) * 2021-01-14 2024-02-01 スパーク セラピューティクス インコーポレイテッド ファブリー病を治療するための組成物および方法
CA3229580A1 (en) * 2021-08-20 2023-02-23 Anna Nikolaevna STRELKOVA Method for producing modified adeno-associated virus capsid
KR20240078666A (ko) * 2021-08-25 2024-06-04 캔브리지 파마슈티컬스, 인크. 간-향성 캡시드 단백질 및 산 알파-글루코시다제(gaa)를 포함하는 aav 입자 및 폼페 질환을 치료하기 위한 이의 용도
AR126870A1 (es) * 2021-08-25 2023-11-22 Canbridge Pharmaceuticals Inc PARTÍCULAS DE AAV QUE COMPRENDEN UNA PROTEÍNA DE LA CÁPSIDE HEPATOTRÓPICA Y a-GALACTOSIDASA Y SU USO PARA TRATAR LA ENFERMEDAD DE FABRY
CA3242731A1 (en) * 2022-02-02 2023-08-10 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
CN118667797A (zh) * 2023-03-14 2024-09-20 北京据德医药科技有限公司 一种重组酸性α-葡萄糖苷酶及其用途
WO2024231820A1 (en) * 2023-05-05 2024-11-14 Takeda Pharmaceutical Company Limited Treatment of pompe disease
US20250041455A1 (en) * 2023-07-28 2025-02-06 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493753B2 (en) 2011-03-16 2016-11-15 Amano Enzyme Inc. Modified α-glucosidase and applications of same
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
HK1206779A1 (en) 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
HUE054087T2 (hu) * 2012-04-18 2021-09-28 Childrens Hospital Philadelphia Készítmények és eljárások nagy hatékonyságú géntranszferre AAV kapszidvariánsok alkalmazásával
WO2015042064A1 (en) * 2013-09-17 2015-03-26 Edeniq, Inc. Improved beta-glucosidase enzymes for increased biomass saccharification
ES2690643T3 (es) * 2013-11-26 2018-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vectores virales adeno-asociados para el tratamiento de enfermedad de almacenamiento de glucógeno
WO2015196179A1 (en) * 2014-06-20 2015-12-23 University Of Florida Research Foundation, Inc. Methods of packaging multiple adeno-associated virus vectors
JP6469127B2 (ja) 2014-10-20 2019-02-13 昭和産業株式会社 新規α−グルコシダーゼ
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
IL299325B2 (en) * 2016-09-12 2025-08-01 Inst Nat Sante Rech Med Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3880823A4 (en) * 2018-11-16 2022-08-17 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus for treating pompe disease

Also Published As

Publication number Publication date
US20250101396A1 (en) 2025-03-27
SG11202011191WA (en) 2020-12-30
EP3794043A4 (en) 2022-02-23
CN112334489A (zh) 2021-02-05
EP3794043A1 (en) 2021-03-24
TW202016310A (zh) 2020-05-01
JP2025066765A (ja) 2025-04-23
KR20210021310A (ko) 2021-02-25
US12084693B2 (en) 2024-09-10
US20210222141A1 (en) 2021-07-22
JP2021523718A (ja) 2021-09-09
PH12020551957A1 (en) 2021-09-20
WO2019222411A1 (en) 2019-11-21
MX2020012332A (es) 2021-02-26
MY207355A (en) 2025-02-21
CL2020002973A1 (es) 2021-07-19
AU2019268363A1 (en) 2021-01-07
CO2020015707A2 (es) 2021-03-19
BR112020023393A2 (pt) 2021-02-09
CA3100213A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
PE20210337A1 (es) CASETES DE EXPRESION DE alfa-GLUCOSIDASA DE ACIDO OPTIMIZADO CON CODON Y METODOS DE USO DEL MISMO
MX2024015050A (es) L-asparaginasa modificada
PE20180505A1 (es) Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres
MX2020013124A (es) Nucleasas guiadas por acido ribonucleico (arn) y fragmentos activos y variantes de los mismos y metodos de uso.
CL2019003561A1 (es) Agentes potenciadores para la transfección celular mejorada y/o la producción del vector raav.
CO2017010807A2 (es) Enzimas y aplicaciones de las mismas
MX2021004282A (es) Construcciones de ácido nucleico y métodos de uso.
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
CO2018005306A2 (es) Variantes del factor viii reducido con cpg, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasia
PE20181026A1 (es) Metodos y composiciones para tolerancia a los herbicidas en plantas
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
BR112022021459A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
AR093626A1 (es) Proteinas de fusion de enzima lisosomal y usos de las mismas
AR089828A1 (es) Variantes de lipasa y polinucleotidos que las codifican
MX2022004345A (es) Construcciones de igf2 variantes.
ES2690386T3 (es) Composición para escindir un ADN diana que comprende un ARN guía específico para el ADN diana y el ácido nucleico que codifica la proteína Cas o la propia proteína Cas, y sus usos
AR059554A1 (es) Acido nucleico derivado de perkinsus marinus que codifica una 9-elongasa, delta 8-desaturasa y delta 5-desaturasa"
AR078374A1 (es) Peptidos aislados de veneno de arana y sus usos como potentes y selectivos bloqueadores del canal ionico
PE20200697A1 (es) Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso
MX2021000421A (es) Métodos y composiciones que usan células dendríticas recombinantes para el tratamiento del cáncer.
AR100310A1 (es) Moléculas para transporte de antígeno modular mejoradas y sus usos
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
MX2021010541A (es) Receptores de linfocitos t y metodos de uso de estos.
MX2021010542A (es) Receptores de linfocitos t y metodos de uso de estos.
MX2018015596A (es) Proteina de fusion entre el factor de viabilidad de los conos derivado de bastones de forma corta y un peptido hidrofilo.